Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss per Share - Basic and Diluted

Net Loss per Share - Basic and Diluted

6 Months Ended

Jun. 30, 2023

Basic and diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding for the time period, which for basic net loss per share, does not include the weighted-average unvested restricted common stock that has been issued and is subject to forfeiture totaling 0 shares for the three months ended June 30, 2023 and 2022, and 40,550 and 0 for the six months ended June 30, 2023 and 2022, respectively.

Dilutive common equivalent shares consist of stock options, warrants, and preferred stock and are calculated using the treasury stock method, which assumes the repurchase of common shares at the average market price during the period. Under the treasury stock method, options and warrants will have a dilutive effect when the average price of common stock during the period exceeds the exercise price of options or warrants. Common equivalent shares do not qualify as participating securities. In periods where the Company records a net loss unvested restricted common stock and potential common stock equivalents are not included in the calculation of diluted net loss per share as their effect would be anti-dilutive. The following is a summary of potential common shares excluded from the calculation of net loss per share as of June 30:


	2023	2022
Common Stock Warrants	13,113,483	157,820
Employee Stock Options	211,126	13,088
Restricted Stock	67,250	2
Preferred Stock	863,602	52
Common Stock Reserved for Future Issuance	15,118	—
Total Shares of Common Stock Issuable	14,270,579	170,962